Skip to main content

Hematologic Neoplasms clinical trials at UC Irvine

3 in progress, 2 open to eligible people

Showing trials for
  • HMPL-306 in Advanced Hematological Malignancies With mIDH

    open to eligible people ages 18 years and up

    An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.

    Orange, California and other locations

  • Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

    open to eligible people ages 18-70

    This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.

    Orange, California

  • CB-Long-Term Safety Study (CB-LTSS)

    Sorry, accepting new patients by invitation only

    This is a non-interventional, long-term safety study of allogeneic CAR-T cell therapy in patients with hematologic malignancies. Its purpose of is to collect long-term observational data to identify and understand potential late side effects in patients who have received CAR-T cell therapies.

    Irvine, California and other locations

Our lead scientists for Hematologic Neoplasms research studies include .